Thought to be a follow-on to Erbitux; In pivotal phase III trials now (Inspire) in nonsquamous lung cancer vs. cisplatin, Alimta, which could be complete by early 2012
Brand N/A Generic necitumumab (formerly known as IMC-11F8)
Company name BMS, Lilly, ImClone Product type Speciality
Therapeutic category Immunologic agents Key uses lung cancer
Other Uses colorectal cancer Drug Class anti-EGFR, fully human IgG1 monoclonal antibody
Dosage From IV Expected Approval 2012+
FDA Filing N/A Last Update date March 02,2010
Link to pipeline report
Link to news article
Link to clinicaltrials.gov